Study of the CD40 Agonistic Monoclonal Antibody APX005M

Inclusion Criteria

• •Histologically documented diagnosis of solid tumor
• •For subjects in the every 2 week and every 1 week dosing cohorts histologically or cytologically documented diagnosis of urothelial carcinoma, melanoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, or any solid tumor with high microsatellite instability status (MSI-high)
• •No known effective therapy options are available
• •Measurable disease by RECIST 1.1
• •ECOG performance status of 0 or 1
• •Adequate bone marrow, liver and kidney function
• •No toxicities related to prior treatment related toxicities with the exception of alopecia and neuropathy
• •Negative pregnancy test for women of child bearing potential